Previous 10 | Next 10 |
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma - 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage - 31% Overall Resp...
IDEAYA Biosciences to Participate in Investor Conferences in December 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company comm...
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: ...
IDEAYA Biosciences (NASDAQ:IDYA): Q3 GAAP EPS of -$0.31 beats by $0.01. Revenue of $8.97M (-0.2% Y/Y) beats by $0.42M. Press Release For further details see: IDEAYA Biosciences EPS beats by $0.01, beats on revenue
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Observed IDE397 preliminary clini...
IDEAYA Biosciences to Participate in Investor Conferences in November 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company commi...
IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer - Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer - Over twenty-year academic career at UT Southwestern and ...
After an all-time high on Wednesday, IDEAYA Biosciences (IDYA -12.7%) has shed more than a tenth of the market cap to record the biggest intraday loss since early July after Stifel started the coverage of the stock with a hold rating. Estimating a price target of $27 per share, the analyst Be...
IDEAYA Biosciences to Participate in Investor Conferences in September 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company co...
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Enrolling MTAP-deletion solid tu...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...